-
Boehringer Ingelheim submits first in class rare psoriasis new drug listing application in China
Time of Update: 2021-11-15
In March 2019, a literature published in the New England Journal of Medicine reported the results of a phase I proof-of-concept clinical study of BI655130 (Spesolimab) in the treatment of patients with generalized pustular psoriasis .
-
Sales of Icotinib and Ensatinib in the third quarter released
Time of Update: 2021-11-15
50%; non-net profit was 326 million yuan, a year-on-year increase of 21.
574 billion yuan in the first 9 months; Ensatinib achieved sales revenue of 65,301,700 yuan in the third quarter, and a total of 120 million yuan in sales in the first 9 months .
-
The diabetes field welcomes new drugs again, PD-1/PD-L1 competition is fierce, and a large number of generic drugs are coming!
Time of Update: 2021-11-15
What to watch this weekWhat to watch this week 1. Shanghai Yizhong's new class 2 drug "Paclitaxel Polymer Micelles for Injection" has been approved for listing! 2. Novo Nordisk's new diabetes drug
-
The market value is 16.78 billion!
Time of Update: 2021-11-15
According to the latest prospectus, the company currently has 87 research projects, of which 10 are Class 1 new drugs and 1 is an improved new drug; Seven injections were approved for production and deemed to have been reviewed, and six were included in the national centralized procurement and all won the bid .
-
CRO rising against the trend: half is sea water, half is flame
Time of Update: 2021-11-15
Recalling the landing of fixed growth in 2020, Zhang Lei once said that Hillhouse will serve as a long-term supporter of Calais to promote in-depth strategic cooperation in new business areas such as small molecules, nucleic acids, biological drugs CDMO, and innovative drug clinical research services .
-
Beihai Kangcheng's CAN008 injection for the treatment of glioblastoma (GBM) completed the first patient administration in a phase II clinical trial in China
Time of Update: 2021-11-15
announced that its Phase II clinical study of CAN008 injection for the treatment of glioblastoma has completed the first patient administration in mainland China .
Beihai Kangcheng has completed the Phase I clinical trial of CAN008 .
-
Novo Nordisk's basal insulin GLP-1RA injection Novo benefit® was approved in China
Time of Update: 2021-11-15
Recently, the National Medical Products Administration approved the marketing application of Novo Nordisk's Novo Nordisk® (Insulin Deglulam and Liraglutide Injection) in China, which is suitable for adults with type 2 diabetes with poor blood sugar control.
-
Merck has reached three consecutive cooperations
Time of Update: 2021-11-15
The study will examine the combination of datopotamab deruxtecan and Keytruda, compared with a single checkpoint inhibitor, and observe and compare the efficacy of the two treatments in untreated patients with high-grade PD-L1 or metastatic non-small cell lung cancer .
-
Shiyao exerts strength, 14 new class 1 drugs are coming intensively this year
Time of Update: 2021-11-15
On October 26, CSPC Zhongqi Pharmaceutical's clinical application for SYHX2001 tablets submitted as a new drug category 1 was accepted by the CDE, and the product was declared for clinical use in China for the first time .
-
Over 1 billion anesthesia blockbuster "Sugeng Sodium Gluconate", Qilu and Huilun two generic drugs were approved on the same day
Time of Update: 2021-11-15
As a widely used and safe muscle relaxant antagonist, Sodium Gluconate, no matter which generic drug is approved for marketing, will benefit the development of the domestic anesthesia field .
-
Hengrui Pharmaceuticals PD-L1 in the treatment of extensive-stage small cell lung cancer phase III clinical study reached the primary endpoint
Time of Update: 2021-11-15
Recently, Hengrui Medicine's new class 1 drug PD-L1 monoclonal antibody SHR-1316 (Adbelizumab injection) combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer is a randomized, double-blind, placebo-controlled, multi-center phase III The main research endpoint of the clinical study (SHR-1316-III-301) reached the pre-specified superiority standard .
-
WHO announces the launch of a vaccine solidarity trial to evaluate the next generation of new coronavirus vaccines
Time of Update: 2021-11-15
According to the latest list of global new crown vaccines released by the World Health Organization, the two vaccines that have been selected for the new crown vaccine unity test are the deoxyribonucleic acid (DNA) vaccine pGX9501/INO- jointly developed by Inovio Pharmaceuticals and Ai Diweixin (Suzhou) Biopharmaceuticals.
-
Withdrawal from the market, plummeted by 77%, the world's first PDC drug was frustrated
Time of Update: 2021-11-15
It is worth mentioning that Pepaxto is the first anti-cancer peptide drug conjugate approved by the FDA Although temporarily frustrated, Oncopeptides said that it will continue to work on the further development of the company's proprietary peptide drug conjugate (PDC) platform, including next-generation drug candidates including OPD5 and OPDC3 .
-
Another breakthrough!
Time of Update: 2021-11-15
The Xinkening bivalent human papillomavirus vaccine has been pre-certified by the World Health Organization, becoming the sixth pre-certified domestic vaccine in China, marking that China’s vaccine product supervision, development and production system and product quality have achieved international standards.
-
Q3 The latest financial report: What breakthroughs have Novartis and Eli Lilly have in the development of innovative therapies?
Time of Update: 2021-11-15
Kisqali is being used as an adjuvant therapy in phase 3 clinical trials to treat patients with early HR-positive and HER2-negative breast cancer In addition, the ABL1 allosteric inhibitor asciminib developed by the company has been granted priority review by the US FDA for the treatment of patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) .
-
Tianjing Biotech and Sinopharm Group reached a strategic cooperation to help China's innovative business transformation to benefit patients
Time of Update: 2021-11-15
, and authorized more than 300 subsidiaries of Sinopharm Holding Group as distributors to carry out retail allocation and terminal sales, and carry out all-round cooperation on key projects to jointly promote Highly differentiated, "best-in-class" and even "world's first" products will enter the Chinese market as soon as possible to meet the actual treatment needs of patients .
-
"Policy Recommendations for Improving Alzheimer's Disease Prevention and Control System" released
Time of Update: 2021-11-15
On October 23, at the 2021 Shanghai Forum on "Healthy Aging-Innovation Helps Precise Prevention, Diagnosis and Treatment of Alzheimer's Disease", under the guidance of the Social Development Research
-
Hengrui, Chia Tai Tianqing, Kangfang... 66 new drugs have been approved for clinical use!
Time of Update: 2021-11-15
BIOTEC and Dongyao sprint; 30 billion PPI drug market, domestically produced Class 1 new drugs are reported for production; The new drugs of Zhengda Tianqing, Kangfang and Poinsettia were approved for clinical use; "Innovative Drug One Brother" broke out!
-
With rapid growth in trials, Chinese pharmaceutical companies are accelerating their transformation from producing generic drugs to developing innovative drugs
Time of Update: 2021-11-14
As the National Medical Products Administration (NMPA) has successively promulgated a number of policies to deepen pharmaceutical reform and encourage innovation, supported by strong compliance supervision, drug clinical trial management practices, and continuously optimized data management methods, domestic pharmaceuticals The value excavated by companies from clinical trials is increasing year by year, which in turn promotes the rapid growth of China's clinical trial market .
-
$20.7 billion!
Time of Update: 2021-11-14
7 billion transaction agreement with Roche to sell Roche’s shares acquired since 20 years ago .
In fact, in the past 20 years, Novartis has also held 1/3 of Roche's bearer shares with voting rights .
